Business
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the
About this update from Guardant Health, Inc.
[{"type":"text","content":" PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 3,333,333 shares of Guardant Health’s common stock at a public offering price of $90.00 per share (the “common stock offering”). The size of the common stock offering was increased from the previously announced $250.0 million of shares of common stock.\n\nIn addition, Guardant Health granted the underwriters an option to purchase up to an additional 499,999 shares of common stock at the public offering price, less underwriting discounts and commissions. The common stock offering is expected to close on November 7, 2025, subject to the satisfaction of customary closing conditions.\n\nGoldman Sachs & Co. LLC, Jefferies, Leerink Partners and Guggenheim Securities are acting as the joint book-running managers for the common stock offering.\n\nGuardant Health estimates that the net proceeds from the common stock offering will be approximately $284.4 million after deducting underwriting discounts and commissions and estimated offering expenses payable by Guardant Health, excluding any exercise of the underwriters’ option to purchase additional shares. Guardant Health intends to use the net proceeds from the common stock offering, together with the net proceeds from Guardant Health’s concurrent convertible notes offering (as defined below), if consummated, for general corporate purposes, which may include, depending on market conditions, repurchasing a portion of Guardant Health’s 0% convertible senior notes due 2027 (the “2027 notes”). General corporate purposes may also include the acquisition of complementary products, technologies, intellectual property or businesses; however, Guardant Health currently does not have any agreements or commitments to complete any such transactions. This press release is not an offer to repurchase any 2027 notes and the common stock offering is not contingent upon the repurchase of any 2027 notes. There can be no assurances that Guardant Health will repurchase any 2027 notes.\n\nIn a separate press release and concurrently with the common stock offering, Guardant Health also announced today the pricing of its previously announced offering of $350.0 million aggregate principal amount of its converti...